论文信息 - Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931 - 字舞流文

Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931

[This corrects the article DOI: 10.3389/fimmu.2018.01355.].

A. Naranjo | J. Maris | W. London | Malcolm A. Smith | R. Seeger | M. Diccianni | A. Yu | K. Messer | B. Shulkin | M. Parisi | C. Reynolds | Julie R. Park | P. Sondel | A. Yu | M. Ozkaynak | C. Reynolds | A. Gilman | Sheena C. Tenney | L. Smith | Karen S. Messer | L. Smith